Skip to main content
Clinical Trials/DRKS00013707
DRKS00013707
Completed
未知

Short term effects of adaptive servoventilation and continuous positive airway pressure in patients with central sleep apnea and Cheyne-Stokes Respiration

Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster0 sites40 target enrollmentMarch 16, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
I50.1
Sponsor
Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster
Enrollment
40
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 16, 2018
End Date
May 1, 2019
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster

Eligibility Criteria

Inclusion Criteria

  • a. Age \> 18 years (no age limit) (Group 1, 2 and 3\)
  • b. able to consent (Group 1, 2 and 3\)
  • c. predominant central sleep apnoea as defined as AHI\>15/h and \>50% central events and a central AHI \>10/h derived from full overnight attended polysomnography (Group 1, 2 and 3\)
  • d. Diagnosis of Nizza class I pumonary arterial Hypertension \-PAH\- and heart failure with reduced ejection fraction \-HFrEF\- according to the most recent Guidelines of the European Society of Cardiology (ESC); \>12 weeks since the diagnosis of HFrEF / PAH has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination therapy for both PAH and HFrEF \-where there was no treatment with combination therapy in PAH patients or with beta blockers or ACE Inhibitors/ARBs in HFrEF, then the reason must be documented\-) (Group 1 and 2\)
  • e. Controls (matched for age and gender) with idopathic central sleep apnoea with normal findings on echocardiogram, electrocardiogram and normal levels of natriuretic peptide hormone (Group 3\)

Exclusion Criteria

  • \- other severe internistic pre\-existing conditions, especially insulin\-dependent diabetes or severe renal impairment \-intake of opiods
  • \- severe psychiatric pre\-existing conditions

Outcomes

Primary Outcomes

Not specified

Similar Trials